PUBLISHER: Grand View Research | PRODUCT CODE: 1529823
PUBLISHER: Grand View Research | PRODUCT CODE: 1529823
Psychiatric Digital Biomarkers Market Trends
The global psychiatric digital biomarkers market was estimated at USD 521.9 million in 2023 and is projected to grow at a CAGR of 23.9% from 2024 to 2030. The increasing prevalence of mental health disorders, advancements in digital health technologies and growing demand for personalized medicine drive the market. Rising adoption of wearable devices and mobile health apps in mental healthcare contribute to the market growth. In April 2024, Sensors published a review on digital phenotyping's impact on neurological diseases, showing its potential to refine clinical trials and aid in early detection and monitoring through telemedicine and sensor technologies.
The global burden of mental health disorders is on the rise, with conditions such as depression, anxiety, bipolar disorder, and schizophrenia affecting millions of people worldwide. In 2023, Mental Health America, Inc. found that 20.17% of youths aged 12-17 had encountered a major depressive episode, with 15% suffering severe impairment affecting daily activities. This increasing prevalence is driving the need for more effective tools to monitor and manage mental health conditions, leading to a growing interest in psychiatric digital biomarkers. In July 2022, Pervasive and Mobile Computing published findings showing significant differences in mood and digital markers (such as sleep and phone usage) between depressed and non-depressed individuals. It also confirmed that depression status could be accurately predicted using these digital biomarkers alone or combined with mood ratings.
Technological advancements in digital health technologies revolutionize the field of mental healthcare. Innovations such as artificial intelligence (AI), machine learning, and data analytics enable the development of sophisticated digital biomarkers that provide valuable insights into an individual's mental health status. AI-powered algorithms analyze data from smartphone sensors to detect changes in behavior patterns that indicate early signs of a mental health crisis.
In November 2023, an article in Frontiers in Psychiatry highlighted the potential of digital biomarkers in predicting and managing mood disorders, noting how smartphone data can monitor depression and treatment responses, wearable devices can track mood disorders more accurately in real-world settings, and AI advancements are opening up new diagnostic and therapeutic avenues.
There is a growing demand for personalized medicine in mental healthcare, as healthcare providers seek to tailor treatment plans to individual patients' needs. Psychiatric digital biomarkers play a crucial role in enabling personalized interventions by providing objective data on patients' symptoms and treatment responses. The increasing adoption of wearable devices and mobile health apps further fuels this trend, allowing for continuous monitoring of patients outside traditional clinical settings. In March 2022, DTU Health Tech researchers developed a method using voice analysis to identify bipolar disorder in individuals and monitor mood changes in patients, with personalized models providing the most accurate results.
Global Psychiatric Digital Biomarkers Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global psychiatric digital biomarkers market report based on type, clinical practice, end use, and region.
U.S.
Canada
Mexico
Germany
UK
France
Italy
Spain
Denmark
Sweden
Norway
China
Japan
India
South Korea
Australia
Thailand
Brazil
Argentina
South Africa
Saudi Arabia
UAE
Kuwait